US 12215322
Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors
granted A61KA61K31/7088A61K38/45
Quick answer
US patent 12215322 (Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 3
- CPC classes
- A61K, A61K31/7088, A61K38/45, A61K38/465, A61P